Table 2 Evolution of Visual acuity during the follow-up
From: Outcomes of trimethoprim/ sulfamethoxazole treatment for ocular toxoplasmosis in Congolese patients
Patients (N = 54) | Affected Eyes (N = 67) | |
|---|---|---|
Initial BCVA | ||
• Normal • Low vision • Blindness | 23 (42.6%) 8 (14.8%) 23 (42.6%) | 33 (49.3%) 8 (11.9%) 26 (38.8%) |
Final BCVA | ||
• Normal • Low vision • Blindness | 36 (66. 7%) 8 (14. 8%) 10 (18. 5%) | 49 (73. 1%) 8 (11. 9%) 10 (15%) |
Evolution of VA | ||
• Improvement • No improvement | 41 (75.9%) 13 (24.1%) | 53 (79.1%) 23 (20.9%) |
Causes of no improvement of VA | ||
• Cataract • Macular scar • Vitreous opacities • Macular edema • Optic atrophy • Epiretinal membrane | 2 (3.7%) 2 (3.7%) 2 (3.7%) 2 (3.7%) 1 (1.8%) 1 (1.8%) | 3 (4.5%) 2 (2.9%) 2 (2.9%) 1 (1.5%) 1 (1.5%) 1 (1.5%) |